对领导和参与科随机临床试验的女性进行系统审查
Sumiya Lodhi1, Taddele Kibret2, Shreepriya Mangalgi3
1Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Kidney international reports
|May 20, 2024
概括
在科随机对照试验 (RCT) 领导和参与中,性别差异仍然存在. 临床研究中的这些不平等在十年内没有改善,需要有针对性的干预措施.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床试验 临床试验
- 研究中的性别平等.
背景情况:
- 妇女在临床研究的领导和参与方面仍然不足.
- 随机对照试验 (RCT) 中现有的性别差异可能会影响研究结果的概括性.
- 科研究和其他领域一样,在实现性别平等方面面临着挑战.
研究的目的:
- 进行科随机对照试验 (RCT) 的文献统计审查.
- 在这些RCT中检查女性在领导职位 (相应,第一和最后的作者) 的代表性.
- 评估女性参与科RCT的参与率,并确定影响这些趋势的因素.
主要方法:
- 2011年至2021年在领先的医学,外科和科期刊上发表的RCT的文献分析.
- 数据提取包括女性的作者地位,试验参与者的人口统计数据,资金来源和试验特征.
- 使用后勤回归分析来确定试验特征与女性领导/参与之间的关联.
主要成果:
- 在395个符合条件的RCT中,女性担任了22%的对应作者,28%的第一作者和19%的最后作者职位,随着时间的推移没有显著变化.
- 女性参与者的中位数为39.0%,没有基于主要作者性别的差异.
- 男性领导的试验不太可能招收女性;女性领导的试验不太可能获得行业资金或领导国际合作.
结论:
- 在科RCT中,领导和参与方面的性别不平等仍然存在.
- 在研究期间,这些差异没有得到改善,这表明需要采取积极的战略.
- 进一步研究和实施有针对性的干预措施对于解决和评估临床试验中的性别平等至关重要.
相关概念视频
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Antihypertensive Drugs: Direct Renin Inhibitors
597
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
597
Factors Affecting Renal Clearance: Renal Impairment
86
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
86
Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
Hazard Ratio
114
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
114


